The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Common Cancer-associated Antigens (CAAs) Vaccine Market Research Report 2025
Synopsis
Perhaps a more cost-effective option lies in developing vaccines using common cancer-associated antigens (CAAs), which in theory could treat a large number of tumours.
The global Common Cancer-associated Antigens (CAAs) Vaccine market was valued at US$ 483 million in 2023 and is anticipated to reach US$ 724.9 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Common Cancer-associated Antigens (CAAs) Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Common Cancer-associated Antigens (CAAs) Vaccine.
Report Scope
The Common Cancer-associated Antigens (CAAs) Vaccine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Common Cancer-associated Antigens (CAAs) Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Common Cancer-associated Antigens (CAAs) Vaccine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Seattle Genetics
Merck Serono
Merck KGaA
GlaxoSmithKline
KAEL-GemVax
SELLAS Life Sciences
Celldex
Immatics Biotechnologies
Segment by Type
Tecemotide
Astuprotimut-R
Tertomotide
Nelipepimut-S
Others
Segment by Application
Pediatrics
Adults
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Common Cancer-associated Antigens (CAAs) Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Perhaps a more cost-effective option lies in developing vaccines using common cancer-associated antigens (CAAs), which in theory could treat a large number of tumours.
The global Common Cancer-associated Antigens (CAAs) Vaccine market was valued at US$ 483 million in 2023 and is anticipated to reach US$ 724.9 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Common Cancer-associated Antigens (CAAs) Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Common Cancer-associated Antigens (CAAs) Vaccine.
Report Scope
The Common Cancer-associated Antigens (CAAs) Vaccine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Common Cancer-associated Antigens (CAAs) Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Common Cancer-associated Antigens (CAAs) Vaccine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Seattle Genetics
Merck Serono
Merck KGaA
GlaxoSmithKline
KAEL-GemVax
SELLAS Life Sciences
Celldex
Immatics Biotechnologies
Segment by Type
Tecemotide
Astuprotimut-R
Tertomotide
Nelipepimut-S
Others
Segment by Application
Pediatrics
Adults
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Common Cancer-associated Antigens (CAAs) Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tecemotide
1.2.3 Astuprotimut-R
1.2.4 Tertomotide
1.2.5 Nelipepimut-S
1.2.6 Others
1.3 Market by Application
1.3.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pediatrics
1.3.3 Adults
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Perspective (2019-2030)
2.2 Common Cancer-associated Antigens (CAAs) Vaccine Growth Trends by Region
2.2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Region (2019-2024)
2.2.3 Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Region (2025-2030)
2.3 Common Cancer-associated Antigens (CAAs) Vaccine Market Dynamics
2.3.1 Common Cancer-associated Antigens (CAAs) Vaccine Industry Trends
2.3.2 Common Cancer-associated Antigens (CAAs) Vaccine Market Drivers
2.3.3 Common Cancer-associated Antigens (CAAs) Vaccine Market Challenges
2.3.4 Common Cancer-associated Antigens (CAAs) Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Revenue
3.1.1 Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Revenue (2019-2024)
3.1.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Players (2019-2024)
3.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Common Cancer-associated Antigens (CAAs) Vaccine Revenue
3.4 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Concentration Ratio
3.4.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Common Cancer-associated Antigens (CAAs) Vaccine Revenue in 2023
3.5 Common Cancer-associated Antigens (CAAs) Vaccine Key Players Head office and Area Served
3.6 Key Players Common Cancer-associated Antigens (CAAs) Vaccine Product Solution and Service
3.7 Date of Enter into Common Cancer-associated Antigens (CAAs) Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Common Cancer-associated Antigens (CAAs) Vaccine Breakdown Data by Type
4.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Type (2019-2024)
4.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Type (2025-2030)
5 Common Cancer-associated Antigens (CAAs) Vaccine Breakdown Data by Application
5.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Application (2019-2024)
5.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2019-2030)
6.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2019-2024)
6.4 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2019-2030)
7.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2019-2024)
7.4 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2019-2030)
8.2 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2019-2024)
8.4 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2019-2030)
9.2 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2019-2024)
9.4 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2019-2030)
10.2 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2019-2024)
10.4 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Seattle Genetics
11.1.1 Seattle Genetics Company Detail
11.1.2 Seattle Genetics Business Overview
11.1.3 Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.1.4 Seattle Genetics Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
11.1.5 Seattle Genetics Recent Development
11.2 Merck Serono
11.2.1 Merck Serono Company Detail
11.2.2 Merck Serono Business Overview
11.2.3 Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.2.4 Merck Serono Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
11.2.5 Merck Serono Recent Development
11.3 Merck KGaA
11.3.1 Merck KGaA Company Detail
11.3.2 Merck KGaA Business Overview
11.3.3 Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.3.4 Merck KGaA Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
11.3.5 Merck KGaA Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Detail
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.4.4 GlaxoSmithKline Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
11.4.5 GlaxoSmithKline Recent Development
11.5 KAEL-GemVax
11.5.1 KAEL-GemVax Company Detail
11.5.2 KAEL-GemVax Business Overview
11.5.3 KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.5.4 KAEL-GemVax Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
11.5.5 KAEL-GemVax Recent Development
11.6 SELLAS Life Sciences
11.6.1 SELLAS Life Sciences Company Detail
11.6.2 SELLAS Life Sciences Business Overview
11.6.3 SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.6.4 SELLAS Life Sciences Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
11.6.5 SELLAS Life Sciences Recent Development
11.7 Celldex
11.7.1 Celldex Company Detail
11.7.2 Celldex Business Overview
11.7.3 Celldex Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.7.4 Celldex Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
11.7.5 Celldex Recent Development
11.8 Immatics Biotechnologies
11.8.1 Immatics Biotechnologies Company Detail
11.8.2 Immatics Biotechnologies Business Overview
11.8.3 Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.8.4 Immatics Biotechnologies Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
11.8.5 Immatics Biotechnologies Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Tecemotide
Table 3. Key Players of Astuprotimut-R
Table 4. Key Players of Tertomotide
Table 5. Key Players of Nelipepimut-S
Table 6. Key Players of Others
Table 7. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region (2019-2024)
Table 11. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region (2025-2030)
Table 13. Common Cancer-associated Antigens (CAAs) Vaccine Market Trends
Table 14. Common Cancer-associated Antigens (CAAs) Vaccine Market Drivers
Table 15. Common Cancer-associated Antigens (CAAs) Vaccine Market Challenges
Table 16. Common Cancer-associated Antigens (CAAs) Vaccine Market Restraints
Table 17. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Players (2019-2024)
Table 19. Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Common Cancer-associated Antigens (CAAs) Vaccine as of 2023)
Table 20. Ranking of Global Top Common Cancer-associated Antigens (CAAs) Vaccine Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Common Cancer-associated Antigens (CAAs) Vaccine Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Common Cancer-associated Antigens (CAAs) Vaccine Product Solution and Service
Table 24. Date of Enter into Common Cancer-associated Antigens (CAAs) Vaccine Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Type (2019-2024)
Table 28. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Type (2025-2030)
Table 30. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Application (2019-2024)
Table 32. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Application (2025-2030)
Table 34. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 49. Seattle Genetics Company Detail
Table 50. Seattle Genetics Business Overview
Table 51. Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 52. Seattle Genetics Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024) & (US$ Million)
Table 53. Seattle Genetics Recent Development
Table 54. Merck Serono Company Detail
Table 55. Merck Serono Business Overview
Table 56. Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 57. Merck Serono Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024) & (US$ Million)
Table 58. Merck Serono Recent Development
Table 59. Merck KGaA Company Detail
Table 60. Merck KGaA Business Overview
Table 61. Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 62. Merck KGaA Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024) & (US$ Million)
Table 63. Merck KGaA Recent Development
Table 64. GlaxoSmithKline Company Detail
Table 65. GlaxoSmithKline Business Overview
Table 66. GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 67. GlaxoSmithKline Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024) & (US$ Million)
Table 68. GlaxoSmithKline Recent Development
Table 69. KAEL-GemVax Company Detail
Table 70. KAEL-GemVax Business Overview
Table 71. KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 72. KAEL-GemVax Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024) & (US$ Million)
Table 73. KAEL-GemVax Recent Development
Table 74. SELLAS Life Sciences Company Detail
Table 75. SELLAS Life Sciences Business Overview
Table 76. SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 77. SELLAS Life Sciences Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024) & (US$ Million)
Table 78. SELLAS Life Sciences Recent Development
Table 79. Celldex Company Detail
Table 80. Celldex Business Overview
Table 81. Celldex Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 82. Celldex Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024) & (US$ Million)
Table 83. Celldex Recent Development
Table 84. Immatics Biotechnologies Company Detail
Table 85. Immatics Biotechnologies Business Overview
Table 86. Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 87. Immatics Biotechnologies Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024) & (US$ Million)
Table 88. Immatics Biotechnologies Recent Development
Table 89. Research Programs/Design for This Report
Table 90. Key Data Information from Secondary Sources
Table 91. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type: 2023 VS 2030
Figure 3. Tecemotide Features
Figure 4. Astuprotimut-R Features
Figure 5. Tertomotide Features
Figure 6. Nelipepimut-S Features
Figure 7. Others Features
Figure 8. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application: 2023 VS 2030
Figure 10. Pediatrics Case Studies
Figure 11. Adults Case Studies
Figure 12. Common Cancer-associated Antigens (CAAs) Vaccine Report Years Considered
Figure 13. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region: 2023 VS 2030
Figure 16. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Players in 2023
Figure 17. Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Common Cancer-associated Antigens (CAAs) Vaccine as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Common Cancer-associated Antigens (CAAs) Vaccine Revenue in 2023
Figure 19. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2019-2030)
Figure 21. United States Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2019-2030)
Figure 25. Germany Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region (2019-2030)
Figure 33. China Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2019-2030)
Figure 41. Mexico Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2019-2030)
Figure 45. Turkey Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Seattle Genetics Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
Figure 48. Merck Serono Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
Figure 49. Merck KGaA Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
Figure 50. GlaxoSmithKline Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
Figure 51. KAEL-GemVax Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
Figure 52. SELLAS Life Sciences Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
Figure 53. Celldex Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
Figure 54. Immatics Biotechnologies Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2019-2024)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
